Search

Your search keyword '"ESSEBAG, VIDAL"' showing total 272 results
Start Over Author "ESSEBAG, VIDAL" Search Limiters Peer Reviewed
272 results on '"ESSEBAG, VIDAL"'

3. Adaptive versus conventional cardiac resynchronisation therapy in patients with heart failure (AdaptResponse): a global, prospective, randomised controlled trial

Author

Wilkoff, Bruce L, Filippatos, Gerasimos, Leclercq, Christophe, Gold, Michael R, Hersi, Ahmad S, Kusano, Kengo, Mullens, Wilfried, Felker, G Michael, Kantipudi, Charan, El-Chami, Mikhael F, Essebag, Vidal, Pierre, Bertrand, Philippon, Francois, Perez-Gil, Francisco, Chung, Eugene S, Sotomonte, Juan, Tung, Stanley, Singh, Balbir, Bozorgnia, Babak, Goel, Satish, Ebert, Hans Holger, Varma, Niraj, Quan, Kara J, Salerno, Fiorella, Gerritse, Bart, van Wel, Janelle, Schaber, Daniel E, Fagan, Dedra H, and Birnie, David

Published
2023
Full Text
View/download PDF

5. Randomized trial of conventional versus radiofrequency needle transseptal puncture for cryoballoon ablation: the CRYO-LATS trial

Author

Andrade, Jason G., Macle, Laurent, Bennett, Matthew T., Hawkins, Nathaniel M., Essebag, Vidal, Champagne, Jean, Roux, Jean-Francois, Makanjee, Bhavanesh, Tang, Anthony, Skanes, Allan, Khaykin, Yaariv, Morillo, Carlos, Jolly, Umjeet, Lockwood, Evan, Amit, Guy, Angaran, Paul, Sapp, John, Wardell, Stephan, Wells, George A., Verma, Atul, and Deyell, Marc W.

Published
2022
Full Text
View/download PDF

6. Characterization of arrhythmia substrate to ablate persistent atrial fibrillation (COAST-AF): Randomized controlled trial design and rationale

Author

Nery, Pablo B., Wells, George A., Verma, Atul, Joza, Jacqueline, Nair, Girish M., Veenhuyzen, George, Andrade, Jason, Nault, Isabelle, Wong, Jorge A., Sikkel, Markus, Essebag, Vidal, Macle, Laurent, Sapp, John, Roux, Jean-Francois, Skanes, Allan, Angaran, Paul, Novak, Paul, Redfearn, Damian, Golian, Mehrdad, Redpath, Calum J., Sturmer, Marcio, and Birnie, David

Published
2022
Full Text
View/download PDF

7. Augmented wide area circumferential catheter ablation for reduction of atrial fibrillation recurrence (AWARE) trial: Design and rationale

Author

Nair, Girish M, Birnie, David H, Wells, George A, Nery, Pablo B, Redpath, Calum J, Sarrazin, Jean-Francois, Roux, Jean-Francois, Parkash, Ratika, Bernier, Martin, Sterns, Laurence D., Novak, Paul, Veenhuyzen, George, Morillo, Carlos A., Singh, Sheldon M., Sturmer, Marcio, Chauhan, Vijay S., Angaran, Paul, and Essebag, Vidal

Published
2022
Full Text
View/download PDF

10. Meta-analysis evaluating apixaban in patients with atrial fibrillation and end-stage renal disease requiring dialysis.

Author

AlTurki, Ahmed, Marafi, Mariam, Dawas, Ahmed, Joza, Jacqueline, Proietti, Riccardo, Russo, Vincenzo, Mavrakanas, Thomas, Trinh, Emilie, Weber, Catherine, Suri, Rita, Essebag, Vidal, and Thao Huynh

Subjects
STROKE prevention, TREATMENT of chronic kidney failure, WARFARIN, THROMBOEMBOLISM prevention, ANTICOAGULANTS, MEDICAL information storage & retrieval systems, INTRACRANIAL hemorrhage, PATIENT safety, GASTROINTESTINAL hemorrhage, CINAHL database, HEMODIALYSIS, TREATMENT effectiveness, META-analysis, DESCRIPTIVE statistics, SYSTEMATIC reviews, ODDS ratio, MEDLINE, ATRIAL fibrillation, MEDICAL databases, CONFIDENCE intervals
Abstract

Background: Warfarin is considered the primary oral anticoagulant for patients with atrial fibrillation and end-stage renal disease (ESRD) requiring dialysis. Although warfarin can offer significant stroke prevention in this population, the accompanying major bleeding risks make warfarin nearly prohibitive. Apixaban was shown to be superior to warfarin in preventing stroke or systemic embolism, with a lower risk of bleeding and mortality in a large, randomized trial of individuals with mostly normal renal function but none with ESRD. Methods: We systematically reviewed evidence comparing apixaban versus warfarin for atrial fibrillation in this population, and evaluated outcomes of stroke or systemic embolism, and major bleeding using random- effects models. The main safety outcome was major bleeding, and the main effectiveness outcome was stroke or systemic embolism. Results: We found five observational studies of 10036 patients (2638 receiving apixaban, and 7398 receiving warfarin) meeting inclusion criteria. Pooled analysis demonstrated a significant reduction in major bleeding with apixaban as compared to warfarin (odds ratio [OR] 0.51, 95% confidence interval [CI] 0.42--0.61; p < .0001). Apixaban was also associated with a reduction in intracranial bleeding (OR 0.58, 95% CI 0.37--0.92; p = .02) and in gastrointestinal bleeding (OR 0.61, 95% CI 0.51--0.73; p < .0001). Furthermore, apixaban was associated with a reduction in stroke/systemic embolism (OR 0.64, 95% CI 0.50--0.82; p < .0001). Conclusion: Apixaban was associated with superior outcomes and reduced adverse events compared to warfarin in observational studies of patients with atrial fibrillation on dialysis. Randomized controlled studies are needed to confirm these findings. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. Risk Factors for Infections Involving Cardiac Implanted Electronic Devices

Author

Birnie, David H., Wang, Jia, Alings, Marco, Philippon, François, Parkash, Ratika, Manlucu, Jaimie, Angaran, Paul, Rinne, Claus, Coutu, Benoit, Low, R. Aaron, Essebag, Vidal, Morillo, Carlos, Redfearn, Damian, Toal, Satish, Becker, Giuliano, Degrâce, Michel, Thibault, Bernard, Crystal, Eugene, Tung, Stanley, LeMaitre, John, Sultan, Omar, Bennett, Matthew, Bashir, Jamil, Ayala-Paredes, Felix, Gervais, Philippe, Rioux, Leon, Hemels, Martin E.W., Bouwels, Leon H.R., Exner, Derek V., Dorian, Paul, Connolly, Stuart J., Longtin, Yves, and Krahn, Andrew D.

Published
2019
Full Text
View/download PDF

16. Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in Atrial Fibrillation (BRAIN-AF): Methods and Design

Author

Rivard, Lena, Khairy, Paul, Talajic, Mario, Tardif, Jean-Claude, Nattel, Stanley, Bherer, Louis, Black, Sandra, Healey, Jeffrey, Lanthier, Sylvain, Andrade, Jason, Massoud, Fadi, Nault, Isabelle, Guertin, Marie-Claude, Dorian, Paul, Kouz, Simon, Essebag, Vidal, Ellenbogen, Kenneth A., Wyse, George, Racine, Normand, Macle, Laurent, Mondesert, Blandine, Dyrda, Katia, Tadros, Rafik, Guerra, Peter, Thibault, Bernard, Cadrin-Tourigny, Julia, Dubuc, Marc, Roux, Jean-Francois, Mayrand, Helene, Greiss, Isabelle, and Roy, Denis

Published
2019
Full Text
View/download PDF

17. Long-Term Outcomes After Ablation for Paroxysmal Atrial Fibrillation Using the Second-Generation Cryoballoon: Final Results From STOP AF Post-Approval Study

Author

Knight, Bradley, Novak, Paul, Sangrigoli, Robert, Champagne, Jean, Dubuc, Marc, Essebag, Vidal, Adler, Stuart, Jain, Sandeep, Svinarich, Thomas, John, Roy, Lockwood, Evan, Gandhi, Gaurang, Wish, Marc, Levy, Matthew, Gassis, Safwat, Johnson, Eric, Seger, John, Remole, Stephen, Collins, H. Wade, III, Oren, Jess, Andrade, Jason, Bernabei, Matthew, Osman, Ahmed, Wu, Richard, Merliss, Andrew, Mansour, Moussa, Miles, William, Su, Wilber, Blatt, Jacob, Seide, Hanscy, Becker, Giuliano, Souza, Joseph, Lloyd, Michael, Cameron, Craig, Baker, James, II, Mitra, Raman, Packer, Douglas, McLeod, Christopher, DeVille, Brian, Compton, Steven, Knight, Bradley P., Novak, Paul G., Adler, Stuart W., Svinarich, J. Thomas, Hokanson, Robert, Kueffer, Fred, Jain, Sandeep K., and John, Roy M.

Published
2019
Full Text
View/download PDF

18. Association Between Patient and Physician Sex and Physician-Estimated Stroke and Bleeding Risks in Atrial Fibrillation

Author

Lee, Hanna, Tan, Mary K., Yan, Andrew T., Angaran, Paul, Dorian, Paul, Bucci, Claudia, Gregoire, Jean C., Bell, Alan D., Green, Martin S., Gross, Peter L., Skanes, Allan, Kerr, Charles R., Mitchell, L. Brent, Cox, Jafna L., Essebag, Vidal, Heilbron, Brett, Ramanathan, Krishnan, Fournier, Carl, Wheeler, Bruce H., Lin, Peter J., Berall, Murray, Langer, Anatoly, Goldin, Lianne, and Goodman, Shaun G.

Published
2019
Full Text
View/download PDF

19. Prevention of Arrhythmia Device Infection Trial: The PADIT Trial

Author

Krahn, Andrew D., Longtin, Yves, Philippon, François, Birnie, David H., Manlucu, Jaimie, Angaran, Paul, Rinne, Claus, Coutu, Benoit, Low, R. Aaron, Essebag, Vidal, Morillo, Carlos, Redfearn, Damian, Toal, Satish, Becker, Giuliano, Degrâce, Michel, Thibault, Bernard, Crystal, Eugene, Tung, Stanley, LeMaitre, John, Sultan, Omar, Bennett, Matthew, Bashir, Jamil, Ayala-Paredes, Felix, Gervais, Philippe, Rioux, Leon, Hemels, Martin E.W., Bouwels, Leon H.R., van Vlies, Bob, Wang, Jia, Exner, Derek V., Dorian, Paul, Parkash, Ratika, Alings, Marco, and Connolly, Stuart J.

Published
2018
Full Text
View/download PDF

20. Cryocure-VT: the safety and effectiveness of ultra-low-temperature cryoablation of monomorphic ventricular tachycardia in patients with ischaemic and non-ischaemic cardiomyopathies.

Author

Verma, Atul, Essebag, Vidal, Neuzil, Petr, Dyrda, Katia, Balt, Jippe, Dinov, Borislav, Darma, Angeliki, Arya, Arash, Sacher, Frederic, Reddy, Vivek Y, Boersma, Lucas, Grigorov, Ilya, and Potter, Tom De

Abstract

Aims The ultra-low-temperature cryoablation (ULTC) ablation system using −196°C N2 cryogen has been reported to create lesions with freeze duration–dependent depth titratable to over 10 mm with minimum attenuation by scar. Cryocure-VT (NCT04893317) was a first-in-human clinical trial evaluating the safety and efficacy of a novel, purpose-built ULTC catheter in endocardial ablation of scar-dependent ventricular tachycardias (VTs). Methods and results This prospective, multi-centre study enrolled patients referred for de novo or second ablations of recurrent monomorphic VT of both ischaemic and non-ischaemic aetiologies. Primary safety and efficacy endpoints of the study were freedom from device- or procedure-related major adverse events (MAEs) up to 30 days post-ablation, acute non-inducibility of clinical VTs at the end of the procedure, and freedom from sustained VT or implantable defibrillator intervention at 6 months. Ultra-low-temperature cryoablation was performed in 64 patients (age 67 ± 11 years, 78% ischaemic, ejection fraction = 35 ± 10%) at 9 centres. The primary acute effectiveness endpoint was achieved in 94% (51/54) of patients in whom post-ablation induction was attempted. There were no protocol-defined MAEs; four procedure-related serious adverse events resolved without clinical sequelae. At 6-month follow-up, 38 patients (60.3%) remained VT-free, and freedom from defibrillator shock was 81.0%, with no significant difference between ischaemic and non-ischaemic cohorts. In 47 patients with defibrillator for at least 6 months prior to the ablation, the VT burden was reduced from median of 4, inter-quartile range (IQR, 1–9) to 0, IQR (0–2). Conclusion In this first-in-human multi-centre experience, endocardial ULTC ablation of monomorphic VT appears safe and effective in patients with both ischaemic-cardiomyopathy and non-ischaemic-cardiomyopathy. Clinical Trial Registration NCT04893317. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. Atrial Fibrillation Burden: Impact on Stroke Risk and Beyond.

Author

AlTurki, Ahmed and Essebag, Vidal

Subjects
ATRIAL fibrillation, STROKE, DISEASE risk factors, ORAL medication
Abstract

Atrial fibrillation (AF) is an important independent risk factor for stroke. Current guidelines handle AF as a binary entity with risk driven by the presence of clinical risk factors, which guides the decision to treat with an oral anticoagulant. Recent studies in the literature suggest a dose–response relationship between AF burden and stroke risk, in both clinical AF and subclinical atrial fibrillation (SCAF), which differs from current guidance to disregard burden and utilize clinical risk scores alone. Within clinical classification and at the same risk levels in various scores, the risk of stroke increases with AF burden. This opens the possibility of incorporating burden into risk profiles, which has already shown promise. Long-term rhythm monitoring is needed to elucidate SCAF in patients with stroke. Recent data from randomized trials are controversial regarding whether there is an independent risk from AF episodes with a duration of less than 24 h, including the duration of SCAF greater than six minutes but less than 24 h. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. Prevention of venous thrombosis after electrophysiology procedures: a survey of national practice

Author

Burstein, Barry, Barbosa, Rodrigo S., Samuel, Michelle, Kalfon, Eli, Philippon, François, Birnie, David, Mangat, Iqwal, Redfearn, Damian, Sandhu, Roopinder, Macle, Laurent, Sapp, John, Verma, Atul, Healey, Jeff S., Becker, Giuliano, Chauhan, Vijay, Coutu, Benoit, Roux, Jean-François, Leong-Sit, Peter, Andrade, Jason G., Veenhuyzen, George D., Joza, Jacqueline, Bernier, Martin, and Essebag, Vidal

Published
2018
Full Text
View/download PDF

28. Use of Evidence-Based Therapy for Cardiovascular Risk Factors in Canadian Outpatients With Atrial Fibrillation: From the Facilitating Review and Education to Optimize Stroke Prevention in Atrial Fibrillation (FREEDOM AF) and Co-ordinated National Network to Engage Physicians in the Care and Treatment of Patients With Atrial Fibrillation (CONNECT AF)

Author

Silberberg, Alexandra, Tan, Mary K., Yan, Andrew T., Angaran, Paul, Dorian, Paul, Bucci, Claudia, Gregoire, Jean C., Bell, Alan D., Gladstone, David J., Green, Martin S., Gross, Peter L., Skanes, Allan, Demchuk, Andrew M., Kerr, Charles R., Mitchell, L. Brent, Cox, Jafna L., Talajic, Mario, Essebag, Vidal, Heilbron, Brett, Ramanathan, Krishnan, Fournier, Carl, Wheeler, Bruce H., Lin, Peter J., Berall, Murray, Langer, Anatoly, Goldin, Lianne, and Goodman, Shaun G.

Published
2017
Full Text
View/download PDF

31. High‐power short‐duration versus low‐power long‐duration ablation for pulmonary vein isolation: A substudy of the AWARE randomized controlled trial.

Author

Joza, Jacqueline, Nair, Girish M., Birnie, David H., Nery, Pablo B., Redpath, Calum J., Sarrazin, Jean‐Francois, Champagne, Jean, Bernick, Jordan, Wells, George A., Essebag, Vidal, Roux, Jean‐Francois, Dussault, Charles, Parkash, Ratika, Bernier, Martin, Sterns, Laurence D., Sapp, John, Novak, Paul, Veenhuyzen, George, Morillo, Carlos A., and Singh, Sheldon M.

Subjects
CONFIDENCE intervals, ATRIAL fibrillation, CATHETER ablation, TREATMENT duration, REGRESSION analysis, TREATMENT effectiveness, COMPARATIVE studies, DESCRIPTIVE statistics, ELECTROCARDIOGRAPHY, RESEARCH funding, PULMONARY veins, PATIENT safety, EVALUATION
Abstract

Introduction: Pulmonary vein isolations (PVI) are being performed using a high‐power, short‐duration (HPSD) strategy. The purpose of this study was to compare the clinical efficacy and safety outcomes of an HPSD versus low‐power, long‐duration (LPLD) approach to PVI in patients with paroxysmal atrial fibrillation (AF). Methods: Patients were grouped according to a HPSD (≥40 W) or LPLD (≤35 W) strategy. The primary endpoint was the 1‐year recurrence of any atrial arrhythmia lasting ≥30 s, detected using three 14‐day ambulatory continuous ECG monitoring. Procedural and safety endpoints were also evaluated. The primary analysis were regression models incorporating propensity scores yielding adjusted relative risk (RRa) and mean difference (MDa) estimates. Results: Of the 398 patients included in the AWARE Trial, 173 (43%) underwent HPSD and 225 (57%) LPLD ablation. The distribution of power was 50 W in 75%, 45 W in 20%, and 40 W in 5% in the HPSD group, and 35 W with 25 W on the posterior wall in the LPLD group. The primary outcome was not statistically significant at 30.1% versus 22.2% in HPSD and LPLD groups with RRa 0.77 (95% confidence interval [CI]) 0.55–1.10; p =.165). The secondary outcome of repeat catheter ablation was not statistically significant at 6.9% and 9.8% (RRa 1.59 [95% CI 0.77–3.30]; p =.208) respectively, nor was the incidence of any ECG documented AF during the blanking period: 1.7% versus 8.0% (RRa 3.95 [95% CI 1.00–15.61; p =.049) in the HPSD versus LPLD group respectively. The total procedure time was significantly shorter in the HPSD group (MDa 97.5 min [95% CI 84.8–110.4)]; p <.0001) with no difference in adjudicated serious adverse events. Conclusions: An HPSD strategy was associated with significantly shorter procedural times with similar efficacy in terms of clinical arrhythmia recurrence. Importantly, there was no signal for increased harm with a HPSD strategy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

33. The 2014 Atrial Fibrillation Guidelines Companion: A Practical Approach to the Use of the Canadian Cardiovascular Society Guidelines

Author

Verma, Atul, Macle, Laurent, Andrade, Jason, Atzema, Clare, Bell, Alan, Cairns, John A., Connolly, Stuart, Cox, Jafna L., Dorian, Paul, Gladstone, David, Healey, Jeff, Leblanc, Kori, Mitchell, L. Brent, Nattel, Stanley, Parkash, Ratika, Pilote, Louise, Sharma, Mike, Skanes, Allan, Talajic, Mario, Tsang, Teresa, Verma, Subodh, Bewick, David, Essebag, Vidal, Guerra, Peter, Heilbron, Brett, Kerr, Charles, Kiaii, Bob, Klein, George, Kouz, Simon, McMurtry, Michael Sean, Ngui, Daniel, Page, Pierre, Pollak, Paul Timothy, Surkes, Jan, Wyse, D. George, and Andrade, Jason G.

Published
2015
Full Text
View/download PDF

36. Risk Stratification and Stroke Prevention Therapy Care Gaps in Canadian Atrial Fibrillation Patients (from the Co-ordinated National Network to Engage Physicians in the Care and Treatment of Patients With Atrial Fibrillation Chart Audit)

Author

Patel, Ashish D., Tan, Mary K., Angaran, Paul, Bell, Alan D., Berall, Murray, Bucci, Claudia, Demchuk, Andrew M., Essebag, Vidal, Goldin, Lianne, Green, Martin S., Gregoire, Jean C., Gross, Peter L., Heilbron, Brett, Lin, Peter J., Ramanathan, Krishnan, Skanes, Allan, Wheeler, Bruce H., and Goodman, Shaun G.

Published
2015
Full Text
View/download PDF

39. Quality of life with ablation or medical therapy for ventricular arrhythmias: A substudy of VANISH

Author

Gula, Lorne J., Doucette, Steve, Leong‐Sit, Peter, Tang, Anthony S.L., Parkash, Ratika, Sarrazin, Jean‐Francois, Thibault, Bernard, Essebag, Vidal, Tung, Stanley K., Deyell, Marc W., Raymond, Jean‐Marc, Lane, Chris, Nery, Pablo B., Veenhuyzen, George D., Redfearn, Damian P., Healey, Jeffrey S., Roux, Jean‐Francois, Giddens, Karen, and Sapp, John L.

Published
2018
Full Text
View/download PDF

45. Snapshot of adult invasive cardiac electrophysiology in Canada: results of the web-based registry

Author

Shurrab, Mohammed, Fishman, Evgeny, Kaoutskaia, Anna, Birnie, David, Ayala-Paredes, Felix, Sultan, Omar, Chauhan, Vijay, Skanes, Allan, Parkash, Ratika, Morillo, Carlos, Janmohamed, Amir, Toal, Satish, Essebag, Vidal, Sterns, Laurence, Veenhuyzen, George, Mangat, Iqwal, Redfearn, Damian, Philippon, François, Connors, Sean, Healey, Jeff, Verma, Atul, and Crystal, Eugene

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results